Administration of nicotinamide mononucleotide in the treatment of disease
US11793824B2 · kind B2 · utility
0Cited by
4References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 15, 2021 |
| Grant date | Oct 24, 2023 |
| Priority date | — |
| Expiry date | Feb 16, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/7064
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are methods and compositions related to methods of treating, ameliorating, mitigating, slowing, arresting, preventing or reversing various diseases and conditions, including age-related obesity, age-related increases in blood lipid levels, age-related decreases in insulin sensitivity, age-related decreases in memory function, and age-related changes in eye function such as macular degeneration. The methods comprise administering nicotinamide mononucleotide (NMN) to a subject. In some embodiments, the administration can be oral administration. Also disclosed are pharmaceutical compositions comprising NMN.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.